Sacituzumab Govitecan Plus EV in Metastatic UC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Urothelial Cancer · Metastatic Urothelial Carcinoma · Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter · Bladder Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Dana Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Bradley A McGregor, MD) · Bmcgregor@partners.org · 617-632-1914
Contact: Principal Investigator (Bradley A McGregor, MD)

Study leads

Bradley A McGregor, MD
Principal Investigator
Dana-Farber Cancer Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract

Urothelial Carcinoma · Cancer

Abroad (travel likely)RecruitingPHASE2

Paris, France · Marseille, France

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

Urothelial Carcinoma · Muscle-invasive Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Orange, United States

Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

Metastatic Urothelial Carcinoma · Unresectable Urothelial Carcinoma · Advanced Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE2

Philadelphia, United States

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Muscle-Invasive Bladder Carcinoma · Metastatic Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE2, PHASE3

Santa Monica, United States